SUDARSHAN PHARMA INDUSTRIES LI (SUDARSHAN.BO)
INR 39.63
(-1.95%)
INR 39.63
(-1.95%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | -705.44 Million | -293.68 Million | -66.2 Million | -79.87 Million | -58.3 Million |
| Net Income | 114.55 Million | 70.36 Million | 52.47 Million | 26.71 Million | 12.75 Million |
| Depreciation & Amortization | 12.44 Million | 9.07 Million | 8.65 Million | 7.42 Million | 3.47 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | -848.62 Million | -376.66 Million | -128.53 Million | -114.64 Million | -80 Million |
| Other non-cash items | 907.61 Million | 197.6 Million | 83.06 Million | 125.13 Million | 85.58 Million |
| Investing Cash Flow | -62.8 Million | -261.42 Million | -17.04 Million | -12.7 Million | -25.39 Million |
| Investments in PPE | -37.83 Million | -138.02 Million | -16.56 Million | -13.19 Million | -24.1 Million |
| Acquisitions | -9.97 Million | - | -483 Thousand | 490 Thousand | - |
| Investment purchases | -15 Million | -123.39 Million | - | - | -1.29 Million |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - |
| Financing Cash Flow | 652.48 Million | 669.93 Million | 73.06 Million | 92.44 Million | 60.79 Million |
| Debt repayment | -661.04 Million | -35.11 Million | -8.21 Million | -89.61 Million | -63.33 Million |
| Dividends payments | -7.22 Million | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | 641.61 Million | 20.19 Million | - | -1.83 Million |
| Other Financing Activities | -1.34 Million | -6.79 Million | 44.65 Million | 2.83 Million | -713 Thousand |
| Accounts receivables | -409.61 Million | -80.32 Million | -130.82 Million | -335.19 Million | -9.61 Million |
| Accounts payables | -352.94 Million | 181.38 Million | 295.33 Million | 291.39 Million | 6.12 Million |
| Inventory | -103.97 Million | -276.98 Million | -229.05 Million | -65.86 Million | -69.66 Million |
| Other working capital | 17.91 Million | -200.73 Million | -63.98 Million | -4.97 Million | -6.84 Million |
| Cash at beginning of period | 178.04 Million | 44.72 Million | 23.87 Million | 14.48 Million | 37.39 Million |
| Cash at end of period | 1.43 Million | 178.04 Million | 44.72 Million | 23.87 Million | 14.48 Million |
| Capital Expenditure | -37.83 Million | -138.02 Million | -16.56 Million | -13.19 Million | -24.1 Million |
| Effect of forex changes on cash | - | 18.49 Million | 31.04 Million | 9.52 Million | - |
| Net cash flow / Change in cash | -176.61 Million | 133.31 Million | 20.85 Million | 9.39 Million | -22.9 Million |
| Free Cash Flow | -743.27 Million | -431.71 Million | -82.76 Million | -93.07 Million | -82.4 Million |
| Breakdown | 2023 FY | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 FY | 2022 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 114.55 Million | - | - | - | 70.36 Million | - |
| Depreciation & Amortization | 12.44 Million | - | - | - | 9.07 Million | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -848.62 Million | - | - | - | -376.66 Million | - |
| Other non-cash items | 907.61 Million | - | - | - | 197.6 Million | - |
| Investing Cash Flow | -62.8 Million | - | - | - | -261.42 Million | - |
| Investments in PPE | -37.83 Million | - | - | - | -138.02 Million | - |
| Acquisitions | -9.97 Million | - | - | - | - | - |
| Investment purchases | -15 Million | - | - | - | -123.39 Million | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 652.48 Million | - | - | - | 669.93 Million | - |
| Debt repayment | -661.04 Million | - | - | - | -35.11 Million | - |
| Dividends payments | -7.22 Million | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | 641.61 Million | - |
| Other Financing Activities | -1.34 Million | - | - | - | -6.79 Million | - |
| Accounts receivables | -409.61 Million | - | - | - | -80.32 Million | - |
| Accounts payables | -352.94 Million | - | - | - | 181.38 Million | - |
| Inventory | -103.97 Million | - | - | - | -276.98 Million | - |
| Other working capital | 17.91 Million | - | - | - | -200.73 Million | - |
| Cash at beginning of period | 178.04 Million | - | - | - | 44.72 Million | - |
| Cash at end of period | 1.43 Million | - | - | - | 178.04 Million | - |
| Capital Expenditure | -37.83 Million | - | - | - | -138.02 Million | - |
| Effect of forex changes on cash | - | - | - | - | 18.49 Million | - |
| Net cash flow / Change in cash | -176.61 Million | - | - | - | 133.31 Million | - |
| Free Cash Flow | -743.27 Million | - | - | - | -431.71 Million | - |
LRCDF
300686
AREXMIS
002719
DOL
300396